Precursor lesions of pancreatic cancer

Pre-Invasive Disease: Pathogenesis and Clinical Management

Volumn , Issue , 2011, Pages 395-420

  Matthaei, Hanno ^a   Maitra, Anirban ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 83055163643     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-6694-0_19     Document Type: Chapter

References (177)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249
2. Maitra A, Hruban RH (2008) Pancreatic cancer. Annu Rev Pathol 3:157-188
3. Lieberman DA (2009) Clinical practice. Screening for colorectal cancer. N Engl J Med 361:1179-1187
4. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet 370:890-907
5. 16-year mortality from breast cancer in the UK Trial of Early Detection of Breast Cancer (1999) Lancet 353:1909-1914.
6. Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784-1792
7. Hulst SPL (1905) Zur kenntnis der genese des adenokarzinoms und karzinoms des pankreas. Virchows Arch 180:288-316
8. Cubilla AL, Fitzgerald PJ (1976) Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res 36:2690-2698
9. Kozuka S, Sassa R, Taki T et al (1979) Relation of pancreatic duct hyperplasia to carcinoma. Cancer 43:1418-1428
10. Andea A, Sarkar F, Adsay VN (2003) Clinicopathological correlates of pancreatic intraepithelial neoplasia: A comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol 16:996-1006
11. Hruban RH, Adsay NV, Albores-Saavedra J et al (2001) Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25:579-586
12. Hruban RH, Takaori K, Klimstra DS et al (2004) An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 28:977-987
13. Brune K, Abe T, Canto M et al (2006) Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol 30:1067-1076
14. Detlefsen S, Sipos B, Feyerabend B, Kloppel G (2005) Pancreatic fibrosis associated with age and ductal papillary hyperplasia. Virchows Arch 447:800-805
15. Hruban RH, Takaori K, Canto M et al (2007) Clinical importance of precursor lesions in the pancreas. J Hepatobiliary Pancreat Surg 14:255-263
16. Maitra A, Adsay NV, Argani P et al (2003) Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 16:902-912
17. Yamano M, Fujii H, Takagaki T, Kadowaki N, Watanabe H, Shirai T (2000) Genetic progression and divergence in pancreatic carcinoma. Am J Pathol 156:2123-2133
18. Biankin AV, Kench JG, Morey AL et al (2001) Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res 61:8830-8837
19. Lohr M, Kloppel G, Maisonneuve P, Lowenfels AB, Luttges J (2005) Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: A meta-analysis. Neoplasia 7:17-23
20. Maitra A, Ashfaq R, Gunn CR et al (2002) Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol 118:194-201
21. Fukushima N, Sato N, Ueki T et al (2002) Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol 160:1573-1581
22. Luttges J, Galehdari H, Brocker V et al (2001) Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol 158:1677-1683
23. Koorstra JB, Hong SM, Shi C et al (2009) Widespread activation of the DNA damage response in human pancreatic intraepithelial neoplasia. Mod Pathol 22:1439-1445
24. Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801-1806
25. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549-554
26. Deramaudt T, Rustgi AK (2005) Mutant KRAS in the initiation of pancreatic cancer. Biochim Biophys Acta 1756:97-101
27. Hingorani SR, Tuveson DA (2003) Ras redux: rethinking how and where Ras acts. Curr Opin Genet Dev 13:6-13
28. Moskaluk CA, Hruban RH, Kern SE (1997) p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 57:2140-2143
29. Hingorani SR, Petricoin EF, Maitra A et al (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4:437-450
30. Hingorani SR, Wang L, Multani AS et al (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7:469-483
31. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10:789-799
32. Wilentz RE, Geradts J, Maynard R et al (1998) Inactivation of the p16 (INK4A) tumorsuppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res 58:4740-4744
33. Caldas C, Hahn SA, da Costa LT et al (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27-32
34. Ueki T, Toyota M, Sohn T et al (2000) Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 60:1835-1839
35. Sherr CJ (2004) Principles of tumor suppression. Cell 116:235-246
36. Lal G, Liu L, Hogg D, Lassam NJ, Redston MS, Gallinger S (2000) Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations. Genes Chromosom Cancer 27:358-361
37. Rulyak SJ, Brentnall TA, Lynch HT, Austin MA (2003) Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome. Cancer 98:798-804
38. Berrozpe G, Schaeffer J, Peinado MA, Real FX, Perucho M (1994) Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer 58:185-191
39. Redston MS, Caldas C, Seymour AB et al (1994) p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 54:3025-3033
40. Sherr CJ, McCormick F (2002) The RB and p53 pathways in cancer. Cancer Cell 2:103-112
41. Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR (1994) An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172:5-12
42. Hahn SA, Schutte M, Hoque AT et al (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350-353
43. Wilentz RE, Su GH, Dai JL et al (2000) Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: A new marker of DPC4 inactivation. Am J Pathol 156:37-43
44. Siegel PM, Massague J (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev 3:807-821
45. Wilentz RE, Iacobuzio-Donahue CA, Argani P et al (2000) Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 60:2002-2006
46. D'Andrea AD, Grompe M (2003) The Fanconi anaemia/BRCA pathway. Nat Rev 3:23-34
47. Shi C, Hruban RH, Klein AP (2009) Familial pancreatic cancer. Arch Pathol Lab Med 133:365-374
48. Jones S, Hruban RH, Kamiyama M et al (2009) Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324:217
49. Goggins M, Hruban RH, Kern SE (2000) BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol 156:1767-1771
50. Griffin CA, Hruban RH, Long PP, Morsberger LA, Douna-Issa F, Yeo CJ (1994) Chromosome abnormalities in pancreatic adenocarcinoma. Genes Chromosom Cancer 9:93-100
51. Moskovitz AH, Linford NJ, Brentnall TA et al (2003) Chromosomal instability in pancreatic ductal cells from patients with chronic pancreatitis and pancreatic adenocarcinoma. Genes Chromosom Cancer 37:201-206
52. Sharpless NE, DePinho RA (2004) Telomeres, stem cells, senescence, and cancer. J Clin Invest 113:160-168
53. Greider CW, Blackburn EH (1996) Telomeres, telomerase and cancer. Sci Am 274:92-97
54. van Heek NT, Meeker AK, Kern SE et al (2002) Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol 161:1541-1547
55. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683-692
56. Omura N, Li CP, Li A et al (2008) Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther 7:1146-1156
57. Tan AC, Jimeno A, Lin SH, et al. (2009) Characterizing DNA methylation patterns in pancreatic cancer genome. Mol Oncol 3(5-6):425-438
58. Jansen M, Fukushima N, Rosty C et al (2002) Aberrant methylation of the 5' CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs. Cancer Biol Ther 1:293-296
59. Sato N, Fukushima N, Matsubayashi H, Iacobuzio-Donahue CA, Yeo CJ, Goggins M (2006) Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma. Cancer 107:251-257
60. Sato N, Fukushima N, Hruban RH, Goggins M (2008) CpG island methylation profile of pancreatic intraepithelial neoplasia. Mod Pathol 21:238-244
61. Sato N, Fukushima N, Maitra A et al (2003) Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 63:3735-3742
62. Fukushima N, Walter KM, Uek T et al (2003) Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice. Cancer Biol Ther 2:78-83
63. Matsubayashi H, Canto M, Sato N et al (2006) DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res 66:1208-1217
64. Porter D, Polyak K (2003) Cancer target discovery using SAGE. Expert Opin Ther Targets 7:759-769
65. Myllykangas S, Junnila S, Kokkola A et al (2008) Integrated gene copy number and expression microarray analysis of gastric cancer highlights potential target genes. Int J Cancer 123:817-825
66. Lin J, Gan CM, Zhang X et al (2007) A multidimensional analysis of genes mutated in breast and colorectal cancers. Genome Res 17:1304-1318
67. Irizarry RA, Ladd-Acosta C, Wen B et al (2009) The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 41:178-186
68. Feinberg AP (2004) The epigenetics of cancer etiology. Semin Cancer Biol 14:427-432
69. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F (2006) The c-Myc target gene network. Semin Cancer Biol 16:253-264
70. Iacobuzio-Donahue CA, Ashfaq R, Maitra A et al (2003) Highly expressed genes in pancreatic ductal adenocarcinomas: A comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 63: 8614-8622
71. Iacobuzio-Donahue CA, Maitra A, Olsen M et al (2003) Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 162: 1151-1162
72. Logsdon CD, Simeone DM, Binkley C et al (2003) Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 63:2649-2657
73. Crnogorac-Jurcevic T, Efthimiou E, Capelli P et al (2001) Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene 20:7437-7446
74. Crnogorac-Jurcevic T, Missiaglia E, Blaveri E et al (2003) Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J Pathol 201:63-74
75. Argani P, Rosty C, Reiter RE et al (2001) Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res 61:4320-4324
76. Argani P, Iacobuzio-Donahue C, Ryu B et al (2001) Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7:3862-3868
77. Ringel J, Lohr M (2003) The MUC gene family: Their role in diagnosis and early detection of pancreatic cancer. Mol Cancer 2:9
78. Levi E, Klimstra DS, Andea A, Basturk O, Adsay NV (2004) MUC1 and MUC2 in pancreatic neoplasia. J Clin Pathol 57:456-462
79. Swartz MJ, Batra SK, Varshney GC et al (2002) MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol 117:791-796
80. Nagata K, Horinouchi M, Saitou M et al (2007) Mucin expression profile in pancreatic cancer and the precursor lesions. J Hepatobiliary Pancreat Surg 14:243-254
81. Moriya T, Kimura W, Semba S et al (2005) Biological similarities and differences between pancreatic intraepithelial neoplasias and intraductal papillary mucinous neoplasms. Int J Gastrointest Cancer 35:111-119
82. Adsay NV, Merati K, Andea A et al (2002) The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol 15:1087-1095
83. Ruiz i Altaba A, Sanchez P, Dahmane N (2002) Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev 2:361-372
84. Artavanis-Tsakonas S, Rand MD, Lake RJ (1999) Notch signaling: cell fate control and signal integration in development. Science 284:770-776
85. Pasca di Magliano M, Sekine S, Ermilov A, Ferris J, Dlugosz AA, Hebrok M (2006) Hedgehog/ Ras interactions regulate early stages of pancreatic cancer. Genes Dev 20:3161-3173
86. Morton JP, Mongeau ME, Klimstra DS et al (2007) Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci U S A 104:5103-5108
87. De La OJ, Emerson LL, Goodman JL et al (2008) Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci U S A 105:18907-18912
88. Thayer SP, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003; doi:10.1038/nature02009
89. Miyamoto Y, Maitra A, Ghosh B et al (2003) Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3:565-576
90. Prasad NB, Biankin AV, Fukushima N et al (2005) Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res 65:1619-1626
91. Plentz R, Park JS, Rhim AD, et al (2009) Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 136(5):1741-1749
92. Rubin LL, de Sauvage FJ (2006) Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov 5:1026-1033
93. Yauch RL, Gould SE, Scales SJ et al (2008) A paracrine requirement for hedgehog signalling in cancer. Nature 455:406-410
94. Feldmann G, Dhara S, Fendrich V et al (2007) Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers. Cancer Res 67:2187-2196
95. Mullendore ME, Koorstra JB, Li YM, et al (2009) Ligand-dependent notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res 15(7):2291-2301
96. Von Hoff DD, Lorusso PM, Rudin CM et al (2009) Inhibition of the hedgehog pathway in advanced Basal-cell carcinoma. N Engl J Med 361:1164-1172
97. Ohhashi K, Murakami F, Maruyama M (1982) Four cases of mucous secreting pancreatic cancer. Prog Dig Endosc 203:348-351
98. Belyaev O, Seelig MH, Muller CA, Tannapfel A, Schmidt WE, Uhl W (2008) Intraductal papillary mucinous neoplasms of the pancreas. J Clin Gastroenterol 42:284-294
99. Ferrone CR, Correa-Gallego C, Warshaw AL et al (2009) Current trends in pancreatic cystic neoplasms. Arch Surg 144:448-454
100. Sohn TA, Yeo CJ, Cameron JL et al (2004) Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 239:788-797, discussion 97-99
101. Salvia R, Fernandez-del Castillo C, Bassi C et al (2004) Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg 239:678-685, discussion 85-87
102. Fernandez-del Castillo C, Targarona J, Thayer SP, Rattner DW, Brugge WR, Warshaw AL (2003) Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg 138:427-423, discussion 33-34
103. Laffan TA, Horton KM, Klein AP et al (2008) Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol 191:802-807
104. Fernandez-del Castillo C, Alsfasser G, Targarona J, Brugge WR, Warshaw AL (2006) Serum CA 19-9 in the management of cystic lesions of the pancreas. Pancreas 32:220
105. Brugge WR, Lewandrowski K, Lee-Lewandrowski E et al (2004) Diagnosis of pancreatic cystic neoplasms: A report of the cooperative pancreatic cyst study. Gastroenterology 126: 1330-1336
106. Allen PJ, Qin LX, Tang L, Klimstra D, Brennan MF, Lokshin A (2009) Pancreatic cyst fluid protein expression profiling for discriminating between serous cystadenoma and intraductal papillary mucinous neoplasm. Ann Surg 250(5):754-760
107. Bassi C, Sarr MG, Lillemoe KD, Reber HA (2008) Natural history of intraductal papillary mucinous neoplasms (IPMN): current evidence and implications for management. J Gastrointest Surg 12:645-650
108. Tanaka M, Kobayashi K, Mizumoto K, Yamaguchi K (2005) Clinical aspects of intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol 40:669-675
109. Tanaka M, Chari S, Adsay V et al (2006) International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6:17-32
110. Rodriguez JR, Salvia R, Crippa S et al (2007) Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology 133:72-79, quiz 309-310
111. Salvia R, Crippa S, Falconi M et al (2007) Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate? Gut 56:1086-1090
112. Chari ST, Yadav D, Smyrk TC et al (2002) Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology 123:1500-1507
113. Kobayashi G, Fujita N, Noda Y et al (2005) Mode of progression of intraductal papillary-mucinous tumor of the pancreas: analysis of patients with follow-up by EUS. J Gastroenterol 40:744-751
114. Salvia R, Partelli S, Crippa S et al (2009) Intraductal papillary mucinous neoplasms of the pancreas with multifocal involvement of branch ducts. Am J Surg 198:709-714
115. Furukawa T, Kloppel G, Volkan Adsay N et al (2005) Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: A consensus study. Virchows Arch 447: 794-799
116. Yonezawa S, Nakamura A, Horinouchi M, Sato E (2002) The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms. J Hepatobiliary Pancreat Surg 9:328-341
117. Adsay NV, Pierson C, Sarkar F et al (2001) Colloid (mucinous noncystic) carcinoma of the pancreas. Am J Surg Pathol 25:26-42
118. Adsay NV, Merati K, Basturk O et al (2004) Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas. Am J Surg Pathol 28:839-848
119. Crippa S, Fernandez-Del Castillo C, Salvia R, et al (2009) Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiological characteristics. Clin Gastroenterol Hepatol 8(2):213-219
120. Schonleben F, Qiu W, Bruckman KC et al (2007) BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Lett 249:242-248
121. Iacobuzio-Donahue CA, Klimstra DS, Adsay NV et al (2000) Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol 157:755-761
122. Sahin F, Maitra A, Argani P et al (2003) Loss of Stk11/Lkb1 expression in pancreatic and biliary neoplasms. Mod Pathol 16:686-691
123. Sato N, Rosty C, Jansen M et al (2001) STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol 159:2017-2022
124. Schonleben F, Qiu W, Ciau NT et al (2006) PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res 12:3851-3855
125. Sato N, Fukushima N, Maitra A et al (2004) Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am J Pathol 164:903-914
126. Croce CM, Calin GA (2005) miRNAs, cancer, and stem cell division. Cell 122:6-7
127. Szafranska AE, Davison TS, John J et al (2007) MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26:4442-4452
128. Lee EJ, Gusev Y, Jiang J et al (2007) Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 120:1046-1054
129. Bloomston M, Frankel WL, Petrocca F et al (2007) MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297:1901-1908
130. Habbe N, Koorstra JB, Mendell JT, et al (2009) MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther 8(4):340-346
131. Klimstra DS (2005) Cystic, mucin-producing neoplasms of the pancreas: the distinguishing features of mucinous cystic neoplasms and intraductal papillary mucinous neoplasms. Semin Diagn Pathol 22:318-329
132. Buscaglia JM, Giday SA, Kantsevoy SV et al (2009) Patient-and cyst-related factors for improved prediction of malignancy within cystic lesions of the pancreas. Pancreatology 9:631-638
133. Garcea G, Ong SL, Rajesh A et al (2008) Cystic lesions of the pancreas. A diagnostic and management dilemma. Pancreatology 8:236-251
134. Fernandez-del Castillo C (2008) Mucinous cystic neoplasms. J Gastrointest Surg 12:411-413
135. Wilentz RE, Albores-Saavedra J, Hruban RH (2000) Mucinous cystic neoplasms of the pancreas. Semin Diagn Pathol 17:31-42
136. Wilentz RE, Albores-Saavedra J, Zahurak M et al (1999) Pathologic examination accurately predicts prognosis in mucinous cystic neoplasms of the pancreas. Am J Surg Pathol 23:1320-1327
137. Crippa S, Salvia R, Warshaw AL et al (2008) Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann Surg 247:571-579
138. Jimenez RE, Warshaw AL, Z'Graggen K et al (1999) Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. Ann Surg 230:501-509, discussion 9-11
139. Iacobuzio-Donahue CA, Wilentz RE, Argani P et al (2000) Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression. Am J Surg Pathol 24:1544-1548
140. Luttges J, Feyerabend B, Buchelt T, Pacena M, Kloppel G (2002) The mucin profile of noninvasive and invasive mucinous cystic neoplasms of the pancreas. Am J Surg Pathol 26:466-471
141. Fukushima N, Sato N, Prasad N, Leach SD, Hruban RH, Goggins M (2004) Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays. Oncogene 23:9042-9051
142. Ornitz DM, Hammer RE, Messing A, Palmiter RD, Brinster RL (1987) Pancreatic neoplasia induced by SV40 T-antigen expression in acinar cells of transgenic mice. Science 238:188-193
143. Quaife CJ, Pinkert CA, Ornitz DM, Palmiter RD, Brinster RL (1987) Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice. Cell 48:1023-1034
144. Jonsson J, Carlsson L, Edlund T, Edlund H (1994) Insulin-promoter-factor 1 is required for pancreas development in mice. Nature 371:606-609
145. Hruban RH, Adsay NV, Albores-Saavedra J et al (2006) Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 66:95-106
146. Aguirre AJ, Bardeesy N, Sinha M et al (2003) Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17:3112-3126
147. Bardeesy N, Aguirre AJ, Chu GC et al (2006) Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A 103:5947-5952
148. Siveke JT, Einwachter H, Sipos B, Lubeseder-Martellato C, Kloppel G, Schmid RM (2007) Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell 12:266-279
149. Izeradjene K, Combs C, Best M et al (2007) Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11:229-243
150. Harsha HC, Kandasamy K, Ranganathan P et al (2009) A compendium of potential biomarkers of pancreatic cancer. PLoS Med 6:e1000046
151. Faca VM, Song KS, Wang H et al (2008) A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 5:e123
152. Funahashi H, Satake M, Dawson D et al (2007) Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res 67:7068-7071
153. Fendrich V, Chen NM, Neef M, et al (2009) The Angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 59(5):630-637
154. Brand RE, Lerch MM, Rubinstein WS et al (2007) Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 56:1460-1469
155. Guerra C, Schuhmacher AJ, Canamero M et al (2007) Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11:291-302
156. Habbe N, Shi G, Meguid RA et al (2008) Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci U S A 105:18913-18918
157. Gidekel Friedlander SY, Chu GC, Snyder EL et al (2009) Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell 16:379-389
158. Pawlik TM, Laheru D, Hruban RH et al (2008) Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol 15: 2081-2088
159. Petersen GM, de Andrade M, Goggins M et al (2006) Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomark Prev 15:704-710
160. Klein AP, Brune KA, Petersen GM et al (2004) Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64:2634-2638
161. Canto MI, Goggins M, Hruban RH et al (2006) Screening for early pancreatic neoplasia in high-risk individuals: A prospective controlled study. Clin Gastroenterol Hepatol 4:766-781, quiz 665
162. Brune K, Abe T, Canto M et al (2006) Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol 30:1067-1076
163. Allen PJ, Brennan MF (2007) The management of cystic lesions of the pancreas. Adv Surg 41:211-228
164. Fasanella KE, McGrath K (2009) Cystic lesions and intraductal neoplasms of the pancreas. Best practice & research 23:35-48
165. Kiely JM, Nakeeb A, Komorowski RA, Wilson SD, Pitt HA (2003) Cystic pancreatic neoplasms: enucleate or resect? J Gastrointest Surg 7:890-897
166. Winter JM, Cameron JL, Lillemoe KD et al (2006) Periampullary and pancreatic incidentaloma: A single institution's experience with an increasingly common diagnosis. Ann Surg 243:673-680, discussion 80-83
167. Fritz S, Warshaw AL, Thayer SP (2009) Management of mucin-producing cystic neoplasms of the pancreas. Oncologist 14:125-136
168. Guarise A, Faccioli N, Ferrari M et al (2008) Evaluation of serial changes of pancreatic branch duct intraductal papillary mucinous neoplasms by follow-up with magnetic resonance imaging. Cancer Imaging 8:220-228
169. Tada M, Kawabe T, Arizumi M et al (2006) Pancreatic cancer in patients with pancreatic cystic lesions: A prospective study in 197 patients. Clin Gastroenterol Hepatol 4:1265-1270
170. Hong SM, Kelly D, Griffith M et al (2008) Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. Mod Pathol 21:1499-1507
171. Riall TS, Stager VM, Nealon WH et al (2007) Incidence of additional primary cancers in patients with invasive intraductal papillary mucinous neoplasms and sporadic pancreatic adenocarcinomas. J Am Coll Surg 204:803-813, discussion 13-14
172. Reid-Lombardo KM, Mathis KL, Wood CM, Harmsen WS, Sarr MG (2009). Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management. Ann Surg 251(1):64-69
173. Baumgaertner I, Corcos O, Couvelard A et al (2008) Prevalence of extrapancreatic cancers in patients with histologically proven intraductal papillary mucinous neoplasms of the pancreas: A case-control study. Am J Gastroenterol 103:2878-2882
174. Yoon WJ, Ryu JK, Lee JK et al (2008) Extrapancreatic malignancies in patients with intraductal papillary mucinous neoplasm of the pancreas: prevalence, associated factors, and comparison with patients with other pancreatic cystic neoplasms. Ann Surg Oncol 15:3193-3198
175. Choi MG, Kim SW, Han SS, Jang JY, Park YH (2006) High incidence of extrapancreatic neoplasms in patients with intraductal papillary mucinous neoplasms. Arch Surg 141:51-56, discussion 6
176. Kamisawa T, Tu Y, Egawa N, Nakajima H, Tsuruta K, Okamoto A (2005) Malignancies associated with intraductal papillary mucinous neoplasm of the pancreas. World J Gastroenterol 11:5688-5690
177. Eguchi H, Ishikawa O, Ohigashi H et al (2006) Patients with pancreatic intraductal papillary mucinous neoplasms are at high risk of colorectal cancer development. Surgery 139:749-754